FDA Accepts Veloxis's Supplemental New Drug Application For De Novo Indication For Envarsus XR

04:00 EDT 24 Apr 2018 | PharmPro

News

The FDA has accepted for standard review the Company's supplemental New Drug Application (sNDA) which seeks a new indication.

Contributed Author:

Veloxis Pharmaceuticals A/S

Topics:

More From BioPortfolio on "FDA Accepts Veloxis's Supplemental New Drug Application For De Novo Indication For Envarsus XR"